Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 20/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464196 | 0.99 | SLC22A2 (0.73) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL79992 | 0.99 | SLC22A2 (0.73) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL4487700 | 0.99 | SLC22A2 (0.73) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL29775486 | 0.99 | SLC22A2 (0.73) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19056214 | 0.99 | SLC22A2 (0.73) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL24603009 | 0.91 | SLC22A2 (0.69) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL4482213 | 0.90 | SLC22A2 (0.70) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL80975 | 0.90 | SLC22A2 (0.70) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL20983475 | 0.90 | SLC22A2 (0.70) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22602568 | 0.89 | SLC22A2 (0.69) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, TYMS, POLA1 | SLC22A2 4555/4885CYP3A4 230/4885TMEM97 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.